文摘
Integrin α4β7 is involved in T cell alloreactivity in acute graft-versus-host disease (GVHD) of the gut. Vedolizumab, a monoclonal antibody, targets the homing of T cells to the intestinal endothelium through inhibition of binding of integrin α4β7. Six patients were treated with vedolizumab for grade IV gut GVHD with clinical responses. The findings presented in this case series give hope for novel therapy of steroid-refractory intestinal GVHD.